BioSpace News Archive

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 41,800 shares of the Company’s common stock at an exercise price per share of $37.56, which was the closing price on January 10, 2022.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced certain unaudited preliminary fourth quarter and full-year 2021 revenue results.

Cigna Corporation, a global health service company, was named one of America’s Most JUST Companies, making this the third year that the organization has been recognized for its corporate citizenship.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), today announced 36-month follow-up results from the 404-patient Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L (MPC-06-ID) in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD).

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Dr. Dajun Yang, the company’s Chairman and CEO, delivered a presentation at the virtually-held 40th Annual J.P. Morgan Healthcare Conference.

Aclaris Therapeutics, Inc. provides an update on the status of certain of its clinical programs and on its research and development operations.

Glaukos Corporation (NYSE: GKOS), today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.

CytoDyn will host an investment community webcast to discuss and provide updates with regard to NASH data results, Cancer, COVID-19, HIV BLA, and finances of the Company on Thursday, January 13, 2022.

Centene announced Leslie V. Norwalk, Esq. has been appointed to the Centene Board of Directors.

ABL Bio, Inc. (KOSDAQ: 298380), today announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson’s disease and other potential indications with enhanced blood-brain barrier (BBB) penetration.